Table 5.

Association between type of antidepressant use at each cycle and invasive breast cancer risk, NHS (2000–2012), and NHSII (2003–2013)

All invasive casesER positiveER negativePostmenopausal at diagnosis
Cases/person-yearsAge and calendar year adjustedFully adjustedaCases/person-yearsFully adjustedaCases/person-yearsFully adjustedaCases/person-yearsFully adjusteda
NHS (n = 2,667 cases)
 None2,345/726,6541 (ref)1 (ref)1,931/726,6541 (ref)295/726,6541 (ref)2,337/726,6421 (ref)
 SSRI194/59,0471.04 (0.90–1.21)0.99 (0.84–1.17)153/59,0470.95 (0.79–1.14)28/59,0471.04 (0.67–1.61)193/59,0460.99 (0.84–1.17)
 Other AD93/25,5441.16 (0.94–1.43)1.13 (0.91–1.40)76/25,5441.13 (0.89–1.44)14/25,5441.20 (0.68–2.11)93/25,5441.13 (0.91–1.41)
 SSRI + Other AD13/4,4800.95 (0.55–1.65)0.93 (0.53–1.62)8/4,4800.69 (0.34–1.39)3/4,4801.62 (0.50–5.25)13/4,4800.93 (0.54–1.63)
NHS II (n= 1,347 cases)
 None1,118/588,4201 (ref)1 (ref)893/588,4201 (ref)182/588,4201 (ref)667/587,5211 (ref)
 SSRI145/80,0010.94 (0.79–1.11)0.83 (0.68–1.02)115/80,0010.80 (0.64–1.01)26/80,0010.98 (0.60–1.58)95/79,8720.83 (0.65–1.06)
 Other AD65/32,7741.03 (0.80–1.32)0.92 (0.71–1.20)57/32,7740.99 (0.75–1.32)7/32,7740.63 (0.29–1.38)46/32,7411.00 (0.73–1.37)
 SSRI + Other AD13/8,4250.80 (0.46–1.38)0.71 (0.40–1.25)11/8,4250.72 (0.39–1.34)1/8,4250.38 (0.05–2.76)8/8,4090.66 (0.32–1.35)
Pooled (n= 4,014 cases)
 None3,463/1,315,0741 (ref)1 (ref)2,824/1,315,0741 (ref)477/1,318,0741 (ref)3,004/1,314,1631 (ref)
 SSRI339/139,0480.99 (0.89–1.11)0.92 (0.77–1.09)268/139,0480.89 (0.75–1.04)54/139,0481.01 (0.73–1.39)288/138,9180.93 (0.79–1.10)
 Other AD158/58,3181.10 (0.94–1.30)1.04 (0.85–1.26)133/58,3181.07 (0.89–1.29)21/58,3180.92 (0.49–1.72)139/58,2851.09 (0.91–1.30)
 SSRI + Other AD26/12,9050.87 (0.59–1.29)0.81 (0.55–1.21)19/12,9050.71 (0.45–1.12)4/12,9050.98 (0.25–3.81)21/12,8890.82 (0.53–1.27)
  • aAdjusted for age, calendar year, BMI, count of clinical depression, age at menarche, current oral contraceptive use (NHSII only), type of PMH use, age at menopause, age at first birth and parity, history of biopsy-confirmed benign breast disease, family history of breast cancer, mammogram in prior 2 years, smoking status, physical activity, alcohol intake, and AHEI score.